Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma by Fabian, ID et al.
Primary	Photodynamic	Therapy	with	Verteporfin	for	Small	Pigmented	Posterior	 1	
Pole	Choroidal	Melanoma	 2	
	 3	
Running	title:	PDT	for	pigmented	choroidal	melanoma	 4	
	 5	
	 6	
1Ido	D	Fabian,	1Andrew	W	Stacey,	1Vasilios	Papastefanou,	1Lamis	Al	Harby,	1Amit	K	 7	
Arora,	1,2Mandeep	S	Sagoo,	1Victoria	M	L	Cohen	 8	
1Moorfields	Eye	Hospital,	2University	College	London	Institute	of	Ophthalmology,	 9	
London,	UK		 10	
	 11	
Keywords:	choroidal	melanoma,	photodynamic	therapy,	verteporfin	 12	
	 13	
Corresponding	author:	Ido	Didi	Fabian,	Moorﬁelds	Eye	Hospital,	162	City	Road,	 14	
London	EC1V	2PD.	 15	
E-mail	address:	didifabian@gmail.com		 16	
Phone	no:	+44	(0)20	72533411	 17	
Fax	no:	+44	(0)20	79002927	 18	
	 19	
Sources	of	support:	none.		 	 20	
2	
	
Abstract	 21	
Purpose:	To	investigate	the	outcomes	of	primary	photodynamic	therapy	(PDT)	for	 22	
small	pigmented	posterior	pole	choroidal	melanoma.		 23	
Methods:	Prospective	interventional	consecutive	case	series	of	15	patients	with	 24	
small	pigmented	posterior	pole	choroidal	melanoma,	who	were	treated	with	3	 25	
sessions	of	PDT	and	followed-up	thereafter.	Risk	factors	for	failure	were	assessed	 26	
and	outcome	measures	at	presentation	were	compared	to	those	at	last	follow-up	 27	
visit.	 28	
Results:	Tumour	control	was	achieved	in	12	(80%)	patients	in	a	median	follow-up	 29	
time	of	15	months	(mean	14,	range	8-18).	Three	patients	failed	treatment,	diagnosed	 30	
in	a	median	time	of	5	months	(mean	4,	range	3-6)	after	first	PDT.	In	all	failed	cases,	 31	
lesions	were	100%	pigmented;	de-novo	melanoma	rather	than	transformed	naevi,	 32	
and	showed	a	radial	growth	pattern	rather	than	increased	thickness.	All	failed	cases	 33	
were	subsequently	successfully	treated	with	radiotherapy.	In	this	cohort,	SRF	was	 34	
significantly	reduced	(p<0.001),	vision	did	not	deteriorate	(p=0.11)	and	even	 35	
improved	in	patients	with	subfoveal	SRF	at	presentation	(p=0.018),	tumour	height	 36	
significantly	decreased	(p=0.037)	and	no	complications	were	recorded.		 37	
Conclusion:	Primary	PDT	was	found	to	be	a	safe	and	efficient	treatment	modality	for	 38	
small	pigmented	posterior	pole	choroidal	melanoma,	achieving	short	term	tumour	 39	
control	in	80%	of	patients.	PDT	offers	patients	the	opportunity	to	preserve	vision	by	 40	
avoiding	the	retinopathy	associated	with	conventional	radiation	treatments	for	 41	
choroidal	melanoma.	However,	the	long-term	local	control	of	these	tumours	remains	 42	
uncertain.		 	 43	
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Introduction	 44	
The	most	commonly	used	treatment	modality	for	choroidal	melanoma	is	 45	
radiotherapy.1	This	treatment,	while	achieving	good	local	control,	results	with	 46	
complications	compromising	vision	in	more	than	50%	of	cases.2	Loss	of	vision	is	often	 47	
accepted	by	patients	who	have	already	experienced	visual	loss	from	medium	and	 48	
large	sized	tumours,	especially	as	larger	tumours	are	associated	with	a	poorer	 49	
survival.3	However,	the	risk	benefit	ratio	is	perceived	less	for	small	posterior	pole	 50	
melanoma	where	vision	may	be	normal	and	survival	figures	are	better.		 51	
Timing	of	treatment	for	an	evolving	melanoma	is	a	matter	of	debate.	While	some	 52	
studies	looked	into	the	risk	factors	for	tumour	growth,4	a	synonym	to	active	 53	
melanoma,	there	is	no	consensus	as	to	how	many	or	what	combination	of	risk	 54	
factors	should	be	present	to		decide	treatment	is	appropriate.	In	light	of	the	 55	
abovementioned,	many	clinicians	are	reluctant	to	treat	small	suspicious	choroidal	 56	
lesions	and	wait	until	there	is	documented	tumour	growth,	especially	if	the	patient	 57	
has	no	visual	symptoms.		 58	
In	search	of	an	ideal	treatment	for	a	small	posterior	pole	choroidal	melanoma,	such	a	 59	
modality	would	result	in	both	high	rate	tumour	control	and	cause	little	or	no	 60	
collateral	damage,	maintaining	visual	function.	Such	a	treatment	would	be	most	 61	
useful	for	patients	diagnosed	in	an	early	stage	of	their	disease	and	who	still	have	 62	
intact	vision,	and	especially	for	those	diagnosed	with	a	tumour	in	an	only	seeing	eye.		 63	
Photodynamic	therapy	(PDT)	with	verteporfin,	potentially,	is	one	such	treatment.	 64	
Originally	used	for	choroidal	neovascularization	in	age-related	macular	 65	
degeneration,5	in	ocular	oncology	it	is	an	efficient	modality	for	selected	cases	of	 66	
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benign	vascular	tumours	and	choroidal	metastasis.6	The	main	mechanism	of	action	 67	
of	PDT	with	verteporfin	is	believed	to	be	the	formation	of	free	oxygen	radicals,	which	 68	
in	turn	cause	damage	to	cellular	components.6	Since	the	treatment	is	localized	and	 69	
does	not	comprise	of	delivering	of	thermal	energy,	minimum	collateral	damage	is	 70	
caused.			 71	
As	primary	treatment	for	choroidal	melanoma,	PDT	was	successfully	used	in	 72	
experimental	animal	studies,7	including	when	verteporfin	was	used	as	a	 73	
photosensitizer.8,9	Clinically,	PDT	with	verteporfin	was	tested	only	in	a	handful	of	 74	
studies	and	case	reports,6,10–14	with	positive	response	in	most.	Interestingly,	while	in	 75	
some	reports	PDT	was	effectively	used	for	both	amelanotic	and	pigmented	 76	
tumours,12	others	raised	doubt	as	to	its	efficacy	in	treating	pigmented	ones.6,14	As	 77	
most	choroidal	melanomas	are	pigmented,	it	is	important	to	investigate	its	role	in	 78	
treating	these	tumours.	We	aimed	in	this	study	to	prospectively	investigate	the	 79	
outcomes	of	primary	PDT	with	verteporfin	for	small	pigmented	posterior	pole	 80	
choroidal	melanomas.		 	 81	
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Subjects	and	Methods	 82	
The	study	was	performed	in	a	prospective	manner	and	approved	by	the	Moorfields	 83	
Eye	Hospital	institutional	review	board	in	concordance	with	the	declaration	of	 84	
Helsinki.	Since	01	April	2014,	all	patients	in	the	London	Ocular	Oncology	Service	with	 85	
small	posterior	pole	choroidal	tumours	were	offered	treatment	with	PDT.	To	be	 86	
included,	tumours	had	to	either	demonstrate	documented	growth,	or	to	have	at	 87	
least	3	risk	factors	for	growth.4	Of	the	risk	factors,	the	presence	of	lipofuscin	was	a	 88	
prerequisite,	to	differentiate	cases	of	choroidal	melanoma	from	leaking	choroidal	 89	
naevi.	Patients	were	also	offered	the	option	of	observation	or	conventional	 90	
treatment	with	plaque	radiotherapy	or	proton	beam	radiotherapy,	according	to	each	 91	
clinical	scenario.	The	potential	benefits	and	disadvantages	of	each	management	 92	
option	were	discussed	and	informed	consent	was	obtained.		 93	
Included	for	analysis	were	tumours	treated	with	3	PDT	sessions	and	followed-up	for	 94	
at	least	6	months	from	first	session.	In	addition,	analysis	was	restricted	to	tumours	 95	
that	were	100%	pigmented	or	partly	pigmented,	defined	as	pigmentation	involving	 96	
at	least	50%	of	the	tumour's	surface	area.		 97	
At	presentation	and	on	ensuing	follow-up	clinical	appointments,	patients	underwent	 98	
a	full	ophthalmic	evaluation,	including	slit	lamp	examination,	color	fundus	imaging,	 99	
autofluorescence,	optical	coherence	tomography	of	the	lesion	and	macula	and	B- 100	
scan	ultrasonography.		 101	
Treatment	protocol	included	an	infusion	of	verteporfin	(Visudyne,	Novartis,	UK),	6mg	 102	
per	m2	body	surface	area	of	over	10	minutes.	Five	minutes	after	infusion	completion	 103	
laser	treatment	commenced.	Parameters	were	set	to	a	light	dose	of	50J/cm2,	power	 104	
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density	of	600mW/cm2,	double	duration	treatment	time	(83	sec	x	2)	and	spot	size	to	 105	
cover	the	entire	lesion.	After	completion	of	treatment,	patients	were	instructed	to	 106	
avoid	exposure	to	direct	light	for	48	hours.	Patients	received	3	PDT	sessions,	4-8	 107	
weeks	apart,	and	were	closely	monitored	thereafter,	once	every	3	months.	At	 108	
completion	of	the	study	all	clinical,	imaging	and	technical	data	were	retrieved	from	 109	
medical	records	and	analyzed.		 110	
	 111	
Data	and	Statistical	Analysis	 112	
For	treatment	success	cases,	variables	from	presentation	and	last	follow-up	visit	 113	
were	used	for	analysis,	whereas	for	failed	treatment	cases	those	at	presentation	and	 114	
at	time	of	failure	were	used.	Treatment	success	was	defined	as	achieving	tumour	 115	
control	after	PDT	and	throughout	follow-up.		 116	
All	calculations	and	plotting	were	completed	using	the	R	Statistical	Environment.	 117	
Continuous	variables	were	evaluated	with	Student	t	tests	and	categorical	variables	 118	
with	Fisher's	Exact	Test.	P-value<0.05	was	considered	significant.	Snellen	acuity	was	 119	
converted	to	logMAR	equivalent.		 	 120	
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Results	 121	
Fifteen	patients	were	found	to	fulfill	the	inclusion	criteria	for	the	study.	There	were	5	 122	
males	and	10	females	at	a	median	age	of	66	years	(mean	64,	range	32-81).	Table	1	 123	
depicts	the	demographic	and	clinical	features	of	the	study	patients	at	presentation	 124	
and	the	PDT	parameters	used.	Four	(27%)	tumours	showed	documented	growth	at	a	 125	
median	time	of	7	years	(mean	8,	range	2-16)	after	first	presentation.	Seven	(47%)	 126	
tumours	were	located	within	one	disc	diameter	(DD)	from	the	fovea	and	10	(67%)	 127	
within	one	DD	from	the	optic	disc	(Figure	1).	Tumour	control	was	achieved	in	12	 128	
(80%)	cases	(Figure	2),	and	for	these,	median	follow-up	time	from	first	PDT	session	 129	
to	last	visit	was	15	months	(mean	14,	range	8-18).		 130	
	 131	
Treatment	failure	 132	
PDT	failed	in	3	cases	(Figure	3),	detected	at	a	median	time	of	5.0	months	(mean	4.3,	 133	
range	2.5-5.5)	from	first	PDT	session	and	2.0	months	(mean	1.8,	range	0.5-3.0)	after	 134	
last	PDT	session.	In	all	3	cases	the	tumours	were	100%	pigmented	and	de-novo.	 135	
Treatment	failure	was	characterized	by	tumour	enlargement	in	base	diameter	rather	 136	
than	in	thickness.	The	median	base	diameter	in	these	3	cases	was	4.9mm	pre-PDT	 137	
(mean	5.3,	range	3-8)	and	6.8mm	post-PDT	(mean	6.8,	range	3.9-9.7).		 138	
One	of	the	failed	treatment	cases	(number	9	in	Figure	1)	was	of	a	relatively	thicker	 139	
tumour	with	apical	height	of	2.7mm.	This	patient	was	originally	offered	plaque	 140	
radiotherapy,	however	declined	treatment	owing	to	concern	regarding	possible	 141	
visual	loss.		 142	
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In	all	3	failure	cases	the	amount	of	SRF	was	reduced	after	PDT,	in	one	it	was	totally	 143	
eliminated.	In	two	cases	logMAR	remained	the	same	after	treatment	and	in	one	it	 144	
improved.	On	statistical	analysis,	none	of	the	demographic	or	clinical	variables	were	 145	
found	to	be	significant	risk	factors	for	failure.	This	was	also	the	case	when	a	 146	
subgroup	analysis	was	performed,	after	excluding	the	pre-treatment	documented	 147	
growth	cases.	The	3	PDT-failed	cases	required	further	treatment,	which	included	 148	
ruthenium	plaque	radiotherapy	(n=2)	and	proton	beam	radiotherapy	(n=1),	they	 149	
continue	to	be	under	surveillance	in	our	clinic	and	show	good	tumour	response	to	 150	
the	radiotherapy.		 151	
	 152	
The	impact	of	PDT	on	subretinal	fluid,	vision	and	tumour	dimensions	and	 153	
treatment	complications	 154	
Figure	4	shows	the	change	in	SRF	over	the	lesion	and	fovea,	logMAR	and	tumour	 155	
height	between	presentation	and	last	follow-up	visit	for	the	whole	cohort.	SRF	was	 156	
detected	in	13	cases	at	presentation,	but	was	only	seen	in	4	cases	at	the	last	follow- 157	
up	visit.	Of	these	4	cases,	the	amount	of	SRF	was	reduced	in	3	after	treatment.	In	 158	
total,	SRF	over	the	lesion	was	reduced	by	a	median	of	-179µm	(mean	-162,	range	0- 159	
395;	p<0.001).	Seven	patients	had	subfoveal	SRF	at	presentation	but	none	of	them	 160	
had	subfoveal	SRF	at	last	follow-up	visit	(p=0.03).		 161	
Median	final	logMAR	visual	acuity	was	0	(mean	0.07,	range	-0.08-0.48).	It	remained	 162	
the	same	or	improved	in	12	out	of	15	of	the	cases,	a	change	that	was	not	found	 163	
statistically	significant	(p=0.11).	A	significant	improvement	in	median	vision	logMAR	 164	
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was	however	found	on	subanalysis	of	patients	with	subfoveal	SRF	at	presentation:	- 165	
0.08	(mean	(-0.12),	range	0.00	–	(-0.24);	p=0.018).		 166	
In	terms	of	tumour	dimensions,	for	the	entire	cohort,	final	median	tumour	thickness	 167	
(median	1.0mm,	mean	1.1mm,	range	0.4-2.6mm)	was	found	to	be	significantly	 168	
reduced	compared	to	presentation	(p=0.037).	Final	tumour	base	diameter	(median	 169	
4.7mm,	mean	4.8mm,	range	2.5-9.7mm)	showed	no	significant	change	as	compared	 170	
to	presentation	(p=0.72).		 171	
No	local	complications	were	recorded	after	PDT	and	throughout	follow-up,	no	 172	
systemic	side	effects	were	reported,	and	none	of	the	patients	developed	metastatic	 173	
disease.		 	 174	
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Discussion	 175	
Our	early	experience	of	treating	small	pigmented	posterior	choroidal	melanoma	is	 176	
encouraging,	especially	as	we	report	on	tumour	control	rate	of	80%.	Furthermore,	 177	
using	this	modality,	treatment	also	resulted	with	significant	reduction	in	SRF,	no	 178	
worsening	of	vision,	significant	anatomical	change,	namely	reduced	tumour	height,	 179	
and	no	treatment	complications.		 180	
	 181	
Treatment	failure	 182	
Treatment	failure	was	documented	in	20%	of	cases.	These	rates	are	higher	 183	
compared	to	juxtapapillary	choroidal	melanoma	treated	with	plaque	radiotherapy,	in	 184	
which	failure	rates	were	3%	at	one	year	and	7%	at	2	years.15	Nevertheless,	close	 185	
follow-up	of	the	failed	cases	enabled	early	detection	of	the	active	tumours,	and	 186	
successful	treatment	with	radiotherapy.	All	PDT-failed	cases	remained	in	the	“small	 187	
tumour”	category	and	their	definitive	treatment	was	delayed	only	by	several	 188	
months,	not	posing	them	at	significant	additional	local	or	systemic	risk.		 189	
All	failed	cases	were	100%	pigmented	and	de-novo	tumours.	It	is	noteworthy	that	in	 190	
all	failure	was	diagnosed	in	a	narrow	time	frame	after	last	PDT	session,	and	most	 191	
interestingly,	all	showed	horizontal	growth	failure	pattern	rather	than	increase	in	 192	
tumour	height.	These	findings	however	were	not	statistically	significant	and	their	 193	
impact	as	potential	risk	factors	for	treatment	failure,	for	the	prior,	or	treatment	 194	
failure	characteristics,	for	the	latter,	is	yet	to	be	determined.		 195	
11	
	
The	impact	of	PDT	on	subretinal	fluid,	vision	and	tumour	dimensions	and	 196	
complications	 197	
For	the	entire	cohort,	SRF	was	significantly	reduced	as	a	result	of	PDT,	a	beneficial	 198	
impact	of	treatment.	The	mechanism	of	action	of	this	effect	is	not	fully	understood	 199	
and	might	be	related	to	choriocapillary	occlusion.8,16	It	remains	to	be	proved	 200	
whether	PDT	has	a	direct	effect	on	the	choroidal	tumour,	or	an	effect	purely	on	its	 201	
vascular	supply,	as	SRF	was	reduced	in	cases	in	which	tumours	remained	active.	 202	
Interestingly,	PDT	also	resulted	with	fluid	elimination	in	cases	of	leaking	choroidal	 203	
naevi,	as	reported	by	Pointdujour-Lim	et	al.17	It	is	important	to	emphasize	that	lack	 204	
of	tumour	growth	after	treatment,	not	resolution	of	SRF,	implies	successful	tumour	 205	
control.	Hence	long	term	follow	up	of	all	cases	is	required	to	fully	determine	the	 206	
success	of	primary	PDT	for	small	choroidal	melanoma.	However,	our	early	results	 207	
coupled	with	close	observation	and	treatment	with	radiotherapy	is	a	useful	strategy	 208	
for	the	treatment	of	these	lesions.	 209	
Visual	acuity	was	found	not	to	worsen	during	the	study	period.	At	final	follow-up	 210	
visit,	14	(93%)	patients	had	vision	of	20/30	or	better,	10	of	which	had	vision	of	20/20	 211	
or	better.	Importantly,	patients	with	SRF	at	the	fovea	showed	a	significant	 212	
improvement	in	visual	acuity,	underscoring	the	cause	for	reduced	vision	on	the	first	 213	
place.		 214	
Two	thirds	of	tumours	in	this	cohort	were	juxtapapillary.	Several	studies	investigated	 215	
the	visual	outcomes	after	radiotherapy	for	juxtapapillary	or	juxtafoveal	choroidal	 216	
melanoma.2,18–20	Recently,	Patel	et	al.	reported	on	their	experience	with	proton	 217	
beam	radiotherapy	as	treatment	for	juxtafoveal	choroidal	melanoma.18	At	 218	
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presentation,	approximately	50%	of	patients	had	vision	of	20/50	or	worse,	 219	
worsening	due	to	radiotherapy	complications	to	over	80%	of	patients	with	vision	in	 220	
that	range,	half	of	which	had	vision	of	counting	fingers	or	worse	at	last	follow-up	 221	
visit.	Of	the	patients	with	tumour	elevation	of	5	mm	or	less	at	presentation,	after	 222	
one	year,	70%	retained	20/40	vision,	dropping	to	approximately	50%	after	2	years.		 223	
Similar	findings	were	reported	also	in	additional	studies.19,20	Visual	outcomes	of	 224	
juxtapapillary	choroidal	melanoma	cases	treated	with	plaque	radiotherapy	were	 225	
reported	by	Sagoo	et	al,2	who	found	that	7%	of	patients	had	final	visual	acuity	of	 226	
20/200	or	worse	after	one	year	and	nearly	20%	at	2	years.	Though	the	initial	Snellen	 227	
acuity	in	that	series	was	not	reported,	53%	of	their	cohort	presented	with	reduced	 228	
visual	acuity.15	In	that	study	most	clinical	factors	predictive	of	poor	final	vision	were	 229	
related	to	tumour	and	plaque	sizes,	radiation	dose	and	tissue	damaged	by	radiation.2	 230	
When	comparing	the	abovementioned	studies	with	the	present	one,	in	terms	of	 231	
visual	function,	juxtapapillary	tumours	are	better	diagnosed	early	and	treated	with	 232	
PDT,	rather	than	at	a	later	stage	and	treated	with	radiation.	It	should	be	stressed	 233	
that	these	clinical	management	suggestions	are	valid	for	juxtapapillary	or	perifoveal	 234	
tumours	where	the	risk	of	permanent	vision	loss	after	radiotherapy	is	high.	Choroidal	 235	
melanoma	located	away	of	the	fovea	and	optic	disc	should	still	be	managed	with	 236	
plaque	brachytherapy	as	this	treatment	may	have	little	or	no	negative	impact	on	 237	
vision.		 238	
Tumour	dimensions	are	important	factors	to	take	into	account	prior	to	using	PDT	for	 239	
pigmented	choroidal	melanoma.	In	our	hands,	and	in	others,	tumours	<2mm	in	 240	
apical	height	benefit	the	most	from	this	treatment	modality.	Canal-Fontcuberta	et	al.	 241	
treated	3	cases	of	pigmented	choroidal	melanoma	>2mm	in	height	with	PDT,	one	of	 242	
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which	was	8.7mm	in	elevation,	and	found	that	treatment	failed	in	all.14	In	contrast,	 243	
Rundle	used	PDT	on	9	patients	with	pigmented	choroidal	melanoma	measuring	 244	
<2mm	in	average	and	found	treatment	to	be	successful	in	8	out	of	9	cases.	 245	
Treatment	failed	in	only	one	case	where	the	melanoma	was	3mm	in	height.12	 246	
Interestingly,	Kim	et	al.	used	PDT	as	treatment	for	pigmented	choroidal	melanomas	 247	
≥3mm	in	apical	height	in	an	in-vivo	animal	model	and	showed	complete	tumour	 248	
arrest	in	all	treated	animals.8	This	however	was	not	shown	in	humans.		 249	
In	terms	of	tumour	response	to	treatment,	interestingly,	PDT	resulted	with	a	 250	
significant	reduction	in	tumour	height,	and	not	only	had	an	impact	on	indirect	 251	
measures,	i.e.	SRF	and	vision.	This,	of	all	variables,	emphasizes	its	beneficial	effect	on	 252	
these	tumours.	The	observed	reduction	in	tumour	height	might	be	related	to	 253	
damaged	tumour	cells	or	local	necrosis	as	a	result	of	occlusion	of	tumour	vascular	 254	
supply.8,16		 255	
Few	complications	of	PDT	are	reported	in	the	literature	and	these	include	transient	 256	
visual	disturbances,	vascular	occlusion,	choroidal	atrophy,	intravitreal	hemorrhage	 257	
and	exudative	retinal	detachment.6	None	of	these	complications	however	occurred	 258	
in	the	present	study.		 259	
The	limitations	of	this	study	include	its	small	cohort	size	and	relatively	short	follow- 260	
up	time.	Nevertheless,	it	provides	significant	information	on	the	outcomes	of	PDT	for	 261	
this	subset	of	patients.	While	all	patients	in	this	study	received	treatment,	some	 262	
might	hold	the	view	that	patients	in	such	an	early	stage	of	their	disease	are	better	 263	
observed,	and	only	treated	when	there	is	documented	growth.	This	issue	is	under	 264	
constant	debate	and	there	is	no	agreement	on	this	management	dilemma.21	 265	
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Nevertheless,	it	is	our	assumption	that	those	who	advocate	observation	first,	prefer	 266	
this	option	as	the	only	modality	currently	available	for	these	tumours	is	radiotherapy	 267	
which	causes	iatrogenic	damage.	In	terms	of	justification	to	treat,	we	selectively	 268	
chose	only	patients	with	3	or	more	risk	factors	for	growth,	of	these,	73%	had	4	or	5	 269	
risk	factors,	and	all	showed	lipofuscin.4,22		 270	
In	summary,	in	this	cohort,	primary	PDT	with	verteporfin	was	found	to	be	an	efficient	 271	
treatment	modality	for	small,	pigmented	posterior	pole	choroidal	melanoma	with	a	 272	
success	rate	of	80%.	Close	follow-up,	once	every	3	months	following	PDT,	enabled	 273	
early	detection	of	growing	tumours	in	3	patients,	all	successfully	treated	with	 274	
radiotherapy.	PDT	resulted	with	significant	reduction	in	SRF,	no	worsening	of	visual	 275	
acuity	and	no	complications.	Longer	follow-up	studies	with	larger	cohorts	are	 276	
required	to	see	if	these	beneficial	results	are	maintained.		 	 277
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Figure	Legend	 347	
Figure	1	 348	
Schematic	diagram	of	tumour	locations	(x	marks	approximate	tumour	center,	+	the	 349	
fovea).	Table	includes	patient’s	corresponding	tumour	height	and	base	diameter.		 350	
*	Patients	who	failed	PDT.		 351	
**	Choroidal	melanoma	with	documented	growth.		 352	
	 353	
Figure	2	 354	
Pigmented	choroidal	lesion	(A;	patient	number	8	in	Figure	1),	2.5mm	from	the	optic	 355	
disc,	with	scattered	lipofuscin	orange	pigment,	corresponding	to	areas	of	hyper- 356	
autofluorescence	(B).	Optical	coherence	tomography	demonstrated	SRF	over	the	 357	
lesion,	but	not	over	the	fovea	(D).	Sixteen	months	after	first	PDT	session,	the	lesion	is	 358	
stable	in	size	(E)	and	SRF	eliminated	(F).		 359	
	 360	
Figure	3	 361	
Pigmented	choroidal	melanoma	(A;	patient	number	3	in	Figure	1),	0.5mm	from	the	 362	
optic	disc,	with	scattered	orange	pigment	and	overlying	SRF	(B).	The	patient	was	 363	
treated	with	3	PDT	sessions;	however	showed	tumour	radial	enlargement	(C),	 364	
detected	5	months	after	first	and	3	months	after	last	PDT	session.	Note	that	despite	 365	
treatment	failure	SRF	over	the	lesion	was	eliminated.	The	patient	was	thereafter	 366	
successfully	treated	with	a	notched	plaque.		 367	
20	
	
	 368	
Figure	4	 369	
Graphs	to	changes	in	clinical	measures	from	presentation	to	last	follow-up	visit,	 370	
including	SRF	over	the	lesion	(n=13,	p<0.001;	A),	SRF	over	the	fovea	(n=7,	p=0.03;	B),	 371	
logMAR	(n=15,	p=0.11;	C)	and	tumour	thickness	(n=15,	p=0.037;	D).		 372	
	 	 373	
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	 375	
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	 377	
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Figure	4	 382	
	 383	
Table	1.	Primary	photodynamic	therapy	with	verteporfin	for	small	pigmented	
choroidal	melanoma	in	15	patients:	Patient’s	demographic	and	clinical	features	
at	presentation	and	treatment	data.		
Features	 Number	 Percentage	
Age	(years)	
										Median	(mean,	range)	
	
66	(64,	32-81)	
	
Gender	
										Male		
										Female	
	
5	
10	
	
33	
67	
Laterality	
										Right	
										Left	
	
8	
7	
	
53	
47	
LogMAR	visual	acuity	in	tumour	eye	
										Median	(mean,	range)	
	
0.18	(0.16,	-0.08-0.48)	
	
LogMAR	visual	acuity	in	fellow	eye	
										Median	(mean,	range)	
	
0.00	(0.15,	-0.10-1.30)	
	
Documented	growth	 4	 27	
24	
	
Number	of	risk	factors	for	growth*	
(n=11)	
	
3	risk	factors	–	3	
4	risk	factors	–	7	
5	risk	factors	-	1	
	
27	
64	
9	
Symptoms	
										Photopsia	
										Blurred	vision	
										None	
	
2	
8	
5	
	
13.3	
53.3	
33.3	
Tumour	dimensions	(mm)	
										Median	(mean,	range)	
	
Height:	1.1	(1.3,	0.9-
2.7)	
Base:	5.0	(4.9,	3.0-8.0)	
	
Distance	of	tumour	from	(mm):	
										Median	(mean,	range)	
	
Optic	disc:	0.5	(1.3,	0-5)	
Fovea:	1.5	(1.7,	0-4)	
	
Presence	of	subretinal	fluid:	
									Above	lesion	
									Subfovea	
	
13	
7	
	
87	
47	
Tumour	pigmentation	
										100%	
										>50%	
	
12	
3	
	
80	
20	
PDT	spot	size	(µm,	summary	of	3	
sessions)	
										Median	(mean,	range)	
	
5600	(5139,	3800-5600)	
	
*	Lesion	thickness	>2mm,	presence	of	subretinal	fluid,	presence	of	lipofuscin,	
related	symptoms	or	margin	to	optic	disc	≤3mm.4		
	 384	
